Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Minerva Neurosciences	Anixa Biosciences	Immutep	Cyclerion Therapeutics	Galectin Therapeutics
Symbol	NASDAQ:NERV	NASDAQ:ANIX	NASDAQ:IMMP	NASDAQ:CYCN	NASDAQ:GALT
Price Information
Current Price	$2.55	$4.28	$3.26	$2.82	$3.47
52 Week Range	Buy	Buy	Buy	N/A	Buy
MarketRank™
Overall Score	1.6	1.4	1.3	1.0	1.4
Analysis Score	3.3	3.5	3.5	0.0	3.5
Community Score	2.8	2.9	2.9	2.5	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	0.0	1.7	0.8
Earnings & Valuation Score	0.0	0.0	0.0	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	N/A	Buy
Consensus Price Target	$6.75	$11.00	$7.00	N/A	$14.00
% Upside from Price Target	164.71% upside	157.01% upside	114.72% upside	N/A	303.46% upside
Trade Information
Market Cap	$107.66 million	$129.18 million	$208.24 million	$93.99 million	$168.61 million
Beta	1.49	1.58	2.23	2.2	2.04
Average Volume	587,679	605,787	2,436,664	639,948	1,682,627
Sales & Book Value
Annual Revenue	N/A	$250,000.00	$4.92 million	$4.51 million	N/A
Price / Sales	N/A	538.10	42.98	21.29	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.71 per share	$0.35 per share	$0.57 per share	$3.56 per share	$0.76 per share
Price / Book	N/A	12.23	5.72	0.79	N/A
Profitability
Net Income	$-72,180,000.00	$-10,020,000.00	$-9,040,000.00	$-123,010,000.00	$-13,290,000.00
EPS	($1.85)	($0.59)	N/A	N/A	($0.39)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	∞	∞	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	-2,322.42%	N/A
Return on Equity (ROE)	-51.19%	-153.08%	N/A	-105.55%	-56.13%
Return on Assets (ROA)	-29.75%	-129.89%	N/A	-57.77%	-49.42%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.26%	N/A	N/A
Current Ratio	6.49%	7.88%	9.26%	4.31%	13.62%
Quick Ratio	6.49%	7.88%	9.26%	4.31%	13.62%
Ownership Information
Institutional Ownership Percentage	66.28%	7.68%	0.16%	68.17%	17.58%
Insider Ownership Percentage	12.00%	23.30%	N/A	10.70%	40.70%
Miscellaneous
Employees	11	3	N/A	34	6
Shares Outstanding	42.72 million	31.43 million	64.87 million	34.06 million	57.16 million
Next Earnings Date	5/3/2021 (Estimated)	6/8/2021 (Estimated)	N/A	5/3/2021 (Estimated)	5/10/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Why Galectin Therapeutics Inc. (NASDAQ:GALT) Is Worth A Spot On Your Watchlist marketingsentinel.com - April 22 at 1:34 PM
	Traders Purchase High Volume of Galectin Therapeutics Call Options (NASDAQ:GALT) americanbankingnews.com - April 22 at 12:48 PM
	Galectin Therapeutics (NASDAQ:GALT) Price Target Raised to $14.00 americanbankingnews.com - April 22 at 8:32 AM
	H.C. Wainwright slashes price target on Galectin Therapeutics Inc. [GALT] – find out why. dbtnews.com - April 20 at 8:47 AM
	If You’re Not Bullish on Galectin Therapeutics Inc. (NASDAQ:GALT) Now, You’ll Kick Yourself Later stocksregister.com - April 19 at 7:29 PM
	Galectin Therapeutics Inc. (NASDAQ:GALT): The Stock for Success Over the Next Few Months marketingsentinel.com - April 19 at 9:29 AM
	World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin finance.yahoo.com - April 19 at 9:29 AM
	Have Insiders Been Selling Galectin Therapeutics Inc. (NASDAQ:GALT) Shares? nasdaq.com - April 18 at 10:55 PM
	Analysts Are Bullish on Top Healthcare Stocks: Galectin Therapeutics (GALT), Stoke Therapeutics (STOK) smarteranalyst.com - April 16 at 1:21 PM
	Company News for Apr 15, 2021 finance.yahoo.com - April 15 at 12:45 PM
	What's Going On With GALT Stock And TV Stock Today? benzinga.com - April 14 at 3:58 PM
	Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response finance.yahoo.com - April 14 at 3:58 PM
	Galectin Gains on Product News baystreet.ca - April 14 at 10:58 AM
	Galectin Therapeutics (GALT) Stock Climbs On Data Publication cnafinance.com - April 14 at 10:58 AM
	Journal for ImmunoTherapy of Cancer Publishes... benzinga.com - April 14 at 12:56 AM
	Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, apnews.com - April 14 at 12:56 AM
	Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy finance.yahoo.com - April 13 at 7:55 PM
	-$0.17 EPS Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This Quarter americanbankingnews.com - April 8 at 4:22 AM
	Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians ... apnews.com - April 7 at 1:00 AM
	Investors Buy High Volume of Galectin Therapeutics Call Options (NASDAQ:GALT) americanbankingnews.com - April 7 at 12:38 AM
	Insider Buying: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Buys 5,000 Shares of Stock americanbankingnews.com - April 6 at 10:42 AM
	Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study finance.yahoo.com - April 6 at 9:28 AM
	Fund L.P. 10X Sells 10,000 Shares of Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock americanbankingnews.com - April 5 at 5:18 PM
	Galectin Therapeutics (NASDAQ:GALT) Announces Quarterly Earnings Results americanbankingnews.com - April 1 at 6:48 PM
	Galectin Therapeutics (NASDAQ:GALT) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS americanbankingnews.com - April 1 at 8:34 AM

Date	Company	Brokerage	Action
9/11/2020	Minerva Neurosciences	William Blair	Reiterated Rating
7/2/2020	Minerva Neurosciences	HC Wainwright	Reiterated Rating
7/1/2020	Minerva Neurosciences	JMP Securities	Reiterated Rating
6/1/2020	Minerva Neurosciences	BTIG Research	Lower Price Target
5/29/2020	Minerva Neurosciences	Jefferies Financial Group	Downgrade
12/2/2019	Minerva Neurosciences	Chardan Capital	Reiterated Rating
8/3/2018	Minerva Neurosciences	Citigroup	Boost Price Target
2/15/2021	Anixa Biosciences	Aegis	Reiterated Rating
12/30/2019	Anixa Biosciences	B. Riley	Lower Price Target
1/26/2021	Immutep	Alliance Global Partners	Boost Price Target
12/14/2020	Immutep	Maxim Group
6/3/2019	Cyclerion Therapeutics	Credit Suisse Group	Initiated Coverage

(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources